Impact of Body Composition on Clinical Outcomes in Metastatic Renal Cell Cancer

Overview

Journal Oncologist

Publisher Oxford University Press

Specialty Oncology

Date 2011 Oct 25

PMID 22020214

Citations 4

Authors

Patricia A Tang

Daniel Y C Heng

Toni K Choueiri

Affiliations

Soon will be listed here.

Citing Articles

Prognostic value of pan-immune-inflammation value and body mass index in geriatric patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors as first line treatment. A single-center retrospective study.

Domanski P, Jarosinska J, Kruczyk B, Pietak M, Mydlak A, Demkow T Contemp Oncol (Pozn). 2024; 27(4):242-248.

PMID: 38405212 PMC: 10883196. DOI: 10.5114/wo.2023.134786.

Impact of obesity on short- and long-term outcomes of laparoscopy assisted distal gastrectomy for gastric cancer.

Shimada S, Sawada N, Ishiyama Y, Nakahara K, Maeda C, Mukai S Surg Endosc. 2017; 32(1):358-366.

PMID: 28656334 DOI: 10.1007/s00464-017-5684-9.

A pilot study of temsirolimus and body composition.

Veasey-Rodrigues H, Parsons H, Janku F, Naing A, Wheler J, Tsimberidou A J Cachexia Sarcopenia Muscle. 2013; 4(4):259-65.

PMID: 23893509 PMC: 3830004. DOI: 10.1007/s13539-013-0113-y.

Body mass index and body surface area and their associations with outcomes in stage II and III colon cancer.

Alipour S, Kennecke H, Woods R, Lim H, Speers C, Brown C J Gastrointest Cancer. 2012; 44(2):203-10.

PMID: 23264206 DOI: 10.1007/s12029-012-9472-4.

References

Ceciliani F, Giordano A, Spagnolo V . The systemic reaction during inflammation: the acute-phase proteins. Protein Pept Lett. 2002; 9(3):211-23. DOI: 10.2174/0929866023408779. View

Antoun S, Birdsell L, Sawyer M, Venner P, Escudier B, Baracos V . Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study. J Clin Oncol. 2010; 28(6):1054-60. DOI: 10.1200/JCO.2009.24.9730. View

Cao Y . Angiogenesis modulates adipogenesis and obesity. J Clin Invest. 2007; 117(9):2362-8. PMC: 1963348. DOI: 10.1172/JCI32239. View

Antoun S, Baracos V, Birdsell L, Escudier B, Sawyer M . Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. Ann Oncol. 2010; 21(8):1594-1598. DOI: 10.1093/annonc/mdp605. View

Leslie N . The redox regulation of PI 3-kinase-dependent signaling. Antioxid Redox Signal. 2006; 8(9-10):1765-74. DOI: 10.1089/ars.2006.8.1765. View

Ladoire S, Bonnetain F, Gauthier M, Zanetta S, Petit J, Guiu S . Visceral fat area as a new independent predictive factor of survival in patients with metastatic renal cell carcinoma treated with antiangiogenic agents. Oncologist. 2011; 16(1):71-81. PMC: 3228050. DOI: 10.1634/theoncologist.2010-0227. View

Awakura Y, Nakamura E, Ito N, Yamasaki T, Kamba T, Kamoto T . Influence of body mass index on prognosis of Japanese patients with renal cell carcinoma. Urology. 2007; 70(1):50-4. DOI: 10.1016/j.urology.2007.03.034. View

Lindblad P, Wolk A, Bergstrom R, Persson I, Adami H . The role of obesity and weight fluctuations in the etiology of renal cell cancer: a population-based case-control study. Cancer Epidemiol Biomarkers Prev. 1994; 3(8):631-9. View

Motzer R, Bacik J, Murphy B, Russo P, Mazumdar M . Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002; 20(1):289-96. DOI: 10.1200/JCO.2002.20.1.289. View

10.

Heaf J . The origin of the 1 x 73-m2 body surface area normalization: problems and implications. Clin Physiol Funct Imaging. 2007; 27(3):135-7. DOI: 10.1111/j.1475-097X.2006.00718.x. View

11.

Dancey J, Dobbin K, Groshen S, Jessup J, Hruszkewycz A, Koehler M . Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clin Cancer Res. 2010; 16(6):1745-55. DOI: 10.1158/1078-0432.CCR-09-2167. View

12.

Chow W, McLaughlin J, Mandel J, Wacholder S, Niwa S, Fraumeni Jr J . Obesity and risk of renal cell cancer. Cancer Epidemiol Biomarkers Prev. 1996; 5(1):17-21. View

13.

Hursting S, Berger N . Energy balance, host-related factors, and cancer progression. J Clin Oncol. 2010; 28(26):4058-65. PMC: 2982796. DOI: 10.1200/JCO.2010.27.9935. View

14.

Pollak M . Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer. 2008; 8(12):915-28. DOI: 10.1038/nrc2536. View

15.

Yoshizumi T, Nakamura T, Yamane M, Islam A, Menju M, Yamasaki K . Abdominal fat: standardized technique for measurement at CT. Radiology. 1999; 211(1):283-6. DOI: 10.1148/radiology.211.1.r99ap15283. View

16.

Motzer R, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J . Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999; 17(8):2530-40. DOI: 10.1200/JCO.1999.17.8.2530. View

17.

Heng D, Xie W, Regan M, Warren M, Golshayan A, Sahi C . Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009; 27(34):5794-9. DOI: 10.1200/JCO.2008.21.4809. View

18.

Kamat A, Shock R, Naya Y, Rosser C, Slaton J, Pisters L . Prognostic value of body mass index in patients undergoing nephrectomy for localized renal tumors. Urology. 2004; 63(1):46-50. DOI: 10.1016/j.urology.2003.08.009. View

19.

Bodine S, Stitt T, Gonzalez M, Kline W, Stover G, Bauerlein R . Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat Cell Biol. 2001; 3(11):1014-9. DOI: 10.1038/ncb1101-1014. View

20.

Chow W, Dong L, Devesa S . Epidemiology and risk factors for kidney cancer. Nat Rev Urol. 2010; 7(5):245-57. PMC: 3012455. DOI: 10.1038/nrurol.2010.46. View